Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Group Threatens to Sue Bayer Over Cancer Claims

By R&D Editors | June 22, 2009

WASHINGTON (AP) – A consumer advocacy group threatened to sue Bayer Healthcare if it continues to claim its One-A-Day vitamins for men reduce the risk of prostate cancer.

The Center for Science in the Public Interest says the company’s ubiquitous TV and radio ads misleadingly claim that a key ingredient of One-A-Day Men’s Health Formula and 50+ Advantage helps prevent cancer.

The group says a study backed by the National Institutes of Health found no evidence the ingredient selenium prevents prostate cancer in men.

“The largest prostate cancer prevention trial has found that selenium is no more effective than a placebo,” said David Schardt, the group’s senior nutritionist. “Bayer is ripping people off when it suggests otherwise in these dishonest ads.”

Researchers halted the study of 35,000 men last October after it became clear that selenium did not prevent prostate cancer, according to the group.

Bayer said Thursday the claims on its vitamins have been approved by the Food and Drug Administration.

“We stand behind all claims made in support of our products,” said Bayer spokeswoman Trisch McKernan.

Bayer’s One-A-Day brand of vitamins had sales of $191 million last year, according to the company’s annual report.

The Center for Science in the Public Interest also sent a letter to the Federal Trade Commission on Thursday asking regulators to halt Bayer’s marketing of the vitamins. The German conglomerate has run at least 11 television ads and 9 radio ads suggesting One-A-Day vitamins can help prevent prostate cancer, according to data from VMS advertising monitoring service.

The letter argues that Bayer’s advertising violates a 2007 agreement with the FTC requiring the company to back up all claims on One-A-Day vitamins with scientific evidence. Bayer entered the agreement after paying a $3.2 million penalty to settle claims that its advertising misled the public about the weight loss benefits of its vitamins.

A spokeswoman for the FTC said Thursday the agency has not yet received the group’s letter.

Date: June 17, 2009
Source: Associated Press

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE